Brief: Candel Therapeutics Q3 Net Income USD -10.646 Million
14/11/2024 13:00
Nov 14 (Reuters) - Candel Therapeutics Q3 operating expenses USD 8.757 million. * Q3 basic EPS USD -0.33 * Q3 income from operations USD -8.757 million
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec